Utilización de colistina en infección por Acinetobacter baumannii multirresistente

• Autores: María Ángeles Allende Bandrés, Mónica Izuel Rami, Herminia Navarro Aznárez, M. C. Viñuales Armengol, Pablo Palomo Palomo
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 5, Nº. 2, 2003, págs. 72-83
• Idioma: español
• Títulos paralelos:
  • Use of colistin in infection by multiresistant Acinetobacter baumannii
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: Analysis of treatments with colistin in patients with infection by multiresistant Acinetobacter baumanii. Methods: Retrospective study of patients (57) with infection by multiresistant Acinetobacter baumanii treated with colistin in 2001. Results: The type of infection was: respiratory (50.9%), from a wound (22.8%), urinary (14%), bacteremia (5.3%) and others (7%). The most important risk factors were: time of stay at the ICU (57.9%), prolonged hospitalization, over 50 years of age (65%) and use of wide-spectrum antibiotics (82.4%). The average dose of colistin was 4.5 million units/day and the average treatment duration was of 14.5 days. The infection evolved favorably in 39 patients. Ten and a half percent of the patients developed renal insufficiency throughout the treatment. Conclusions: 1) The most frequent and of worst prognosis infection was the respiratory one. 2) The treatments have been well tolerated